NCT00002408已完成3 期
A Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Orally Administered SP-303 for the Treatment of Diarrhea in Acquired Immunodeficiency Syndrome (AIDS) Patients
Shaman Pharmaceuticals71 个研究点 分布在 2 个国家目标入组 300 人开始时间: 2001年8月31日最近更新:
适应症
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 300
- 试验地点
- 71
研究概览
简要总结
To evaluate the efficacy, safety, and durability of response of SP-303 in decreasing stool weight in AIDS patients with diarrhea over 6 days of treatment.
研究设计
- 研究类型
- Interventional
- 主要目的
- Treatment
- 盲法
- Double
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients must have:
- •HIV infection meeting CDC criteria for AIDS.
- •History of diarrhea for greater than or equal to 14 days prior to screening period (Day 1).
- •- On stable medical regimen.
排除标准
- 未提供
研究者
研究点 (71)
Loading locations...
相似试验
已完成
2 期
Safety and Efficacy Study of S-309309 in Obese AdultsObesityNCT05925114Shionogi365
已完成
2 期
Dose-ranging Study to Assess Safety and Efficacy of SP-333 for the Treatment of Opioid-induced Constipation (OIC)ConstipationNCT01983306Bausch Health Americas, Inc.292
终止
3 期
Zephyrus I: Evaluation of Efficacy and Safety of Pamrevlumab in Participants With Idiopathic Pulmonary Fibrosis (IPF)Idiopathic Pulmonary FibrosisNCT03955146FibroGen356
已完成
2 期
An Efficacy, Safety and Pharmacokinetics Study of Beloranib (ZGN-440 for Injectable Suspension) in Obese SubjectsObesityNCT01666691Zafgen, Inc.160
已完成
4 期
Phase IV Study of Qsymia in Obese PatientsObesityNCT05378503Alvogen Korea232